Please assess the completion status of the following clinical trial:

Trial Title: A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant with GD1 currently being treated with an ERT/SRT other than VPRIV for at least 6 months before baseline enrolment; or participant previously treated with another ERT/ SRT for at least 6 months prior to transitioning to VPRIV..~* Participant or legally authorized representative has provided written informed consent.~Exclusion Criteria:~* In the opinion of the investigator, participant is at high risk of non-compliance.~* In the opinion of the investigator, participant is unsuitable in any other way to participate in this study.~* Participant is pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VPRIV Participants (Type: None): Participants who has been transitioned from ERTs/SRTs to VPRIV, the data will be collected retrospectively from time of transition until the point at which participant begins in this study and then will be followed up prospectively for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).